A pill for relapsed or refractory follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an investigational pill (SHR2554) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if the pill can shrink the lymphoma and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with follicular lymphoma, a type of non-Hodgkin lymphoma.
- Your lymphoma has not responded to treatment or has come back after treatment with a CD20 antibody (like rituximab).
- You are able to take care of yourself and are up and about at least half of the day (ECOG score of 2 or less).
- You have at least one tumor that can be measured on scans.
- You do not have active infections, serious heart problems, or other cancers (within the last 5 years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
This trial tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) for people newly diagnosed with follicular lymphoma. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a new drug called SHR-3079 for people with B-cell non-Hodgkin lymphoma whose cancer did not get better or came back after at least one standard treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
This study tests a new drug (IMM0306) combined with lenalidomide, compared to a placebo with lenalidomide, for people with follicular lymphoma that has come back or not responded to treatment. The goal is to see if adding IMM0306 helps control the cancer better.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.